| 8.62 0.04 (0.47%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.88 | 1-year : | 14.83 |
| Resists | First : | 11.03 | Second : | 12.69 |
| Pivot price | 9.45  |
|||
| Supports | First : | 8.32 | Second : | 6.93 |
| MAs | MA(5) : | 8.63 |
MA(20) : | 10.01 |
| MA(100) : | 11.06 |
MA(250) : | 12.49 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 8.8 |
D(3) : | 7.4 |
| RSI | RSI(14): 30.8 |
|||
| 52-week | High : | 18.22 | Low : | 8.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DCTH ] has closed above bottom band by 19.0%. Bollinger Bands are 27.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.64 - 8.7 | 8.7 - 8.75 |
| Low: | 8.28 - 8.34 | 8.34 - 8.39 |
| Close: | 8.54 - 8.64 | 8.64 - 8.71 |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Thu, 06 Nov 2025
Delcath Systems to Participate in Upcoming November 2025 Investor Conferences - BioSpace
Thu, 06 Nov 2025
Delcath Systems, Inc. (NASDAQ:DCTH) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 06 Nov 2025
Delcath: Temporary Headwinds Are No Cause For Concern (NASDAQ:DCTH) - Seeking Alpha
Thu, 06 Nov 2025
Stephens Has Lowered Expectations for Delcath Systems (NASDAQ:DCTH) Stock Price - MarketBeat
Wed, 05 Nov 2025
Delcath Systems (DCTH): Profitability Turn Challenges Bearish Sentiment as Growth Forecasts Top Market Averages - Sahm
Wed, 05 Nov 2025
Delcath Systems (DCTH) Analyst Rating Update: Price Target Lowered to $18 | DCTH Stock News - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 35 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 53.1 (%) |
| Shares Short | 4,770 (K) |
| Shares Short P.Month | 3,200 (K) |
| EPS | 0.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3 |
| Profit Margin | 3.1 % |
| Operating Margin | 10.7 % |
| Return on Assets (ttm) | 4.1 % |
| Return on Equity (ttm) | 3.5 % |
| Qtrly Rev. Growth | 211 % |
| Gross Profit (p.s.) | 1.72 |
| Sales Per Share | 2 |
| EBITDA (p.s.) | 0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 5 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | 95.77 |
| PEG Ratio | 0 |
| Price to Book value | 2.87 |
| Price to Sales | 4.29 |
| Price to Cash Flow | 62.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|